Optimizing Initial Dosing for Tacrolimus and Mycophenolate in Living Donor Liver Transplantation: A Systematic Critical Review.

Ther Drug MonitMay 28, 2026 (epub)
Clinical ResearchGastroenterologyInternal Medicine (General)

Kiara Bautista, Jeong Park

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the pharmacokinetics of tacrolimus and mycophenolate in living donor liver transplantation (LDLT) recipients. It found that LDLT recipients may require 30%-50% lower initial doses of tacrolimus compared to deceased donor liver transplantation (DDLT) recipients, while mycophenolate dosing should remain consistent. The review analyzed 16 studies on these medications.

Key findings

  • LDLT recipients may need 30%-50% lower initial doses of tacrolimus than DDLT recipients.
  • CYP3A5 polymorphisms in donors and recipients affect tacrolimus exposure variability.
  • Limited evidence exists regarding mycophenolate dosing adjustments in LDLT recipients.

Why it matters

Understanding the pharmacokinetic differences in immunosuppressive agents between LDLT and DDLT recipients is crucial for optimizing patient outcomes and minimizing the risk of drug toxicity or rejection.

Source

PubMed · PMID 42208050

Published in Ther Drug Monit. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.